Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISRITUX: Discontinuation vs maintenance rituximab in ANCA-associated vasculitis
2023-508398-10-00Phase 4Authorised
- Sponsor
- Region Östergötland
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 4, randomised, open-label trial of rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by Region Östergötland. Primary endpoint: Disease relapse rate. Planned start Jun 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2023-508398-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508398-10-00.